Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer

Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer

Abstract The objective of this study is to compare the efficacy of apalutamide and bicalutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We retrospectively collected the data of about 330 patients with metastatic hormone-...

Full description

Bibliographic Details
Main Authors: Takashi Ueda, Takumi Shiraishi, Masatsugu Miyashita, Naruhiro Kayukawa, Yusuke Gabata, Satoshi Sako, Ryota Ogura, Atsuko Fujihara, Koji Okihara, Osamu Ukimura
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-51389-w

Internet

https://doi.org/10.1038/s41598-024-51389-w

Similar Items